<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576277</url>
  </required_header>
  <id_info>
    <org_study_id>AV411-010</org_study_id>
    <nct_id>NCT00576277</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain</brief_title>
  <official_title>A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial of AV411 to Assess Its Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in the Treatment of Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avigen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
      AV411 after single and multiple doses in patients with chronic neuropathic pain due to
      diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic profile</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of analgesic or adjuvant medications for neuropathic pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between plasma concentrations of AV411 and pain intensity assessments</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV411</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetic neuropathy or complex regional pain syndrome of at least 6
             months duration

          -  VAS score of 4 cm or higher at Screening

          -  No clinical abnormality in laboratory and urine analyses

          -  Electrocardiogram within normal limits at Screening

          -  Negative pregnancy test on Study Day 1 for female subjects of childbearing potential

          -  On stable doses of medications, analgesic or others for at least 8 weeks prior to
             study enrollment

          -  Willing to use barrier contraceptive during the period of the study

        Exclusion Criteria:

          -  Known hypersensitivity to AV411 or its components

          -  Conditions which might affect drug absorption, metabolism or excretion

          -  Untreated mental illness, current drug addiction or abuse or alcoholism

          -  Donated blood in the past 90 days or have poor peripheral venous access

          -  Platelets &lt;100,000mm3 or a history of thrombocytopenia

          -  Known or suspected chronic liver disease

          -  GFR &lt;=90mL/min/1.73m2 (Cockcroft-Gault)

          -  Female subjects who are pregnant or nursing mothers

          -  Received an investigational drug in the past 90 days

          -  Unable to swallow large capsules
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Adelaide</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsular Specialist Centre</name>
      <address>
        <city>Kipparing</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

